Curavit Clinical Research is a Boston-based, all-virtual Contract Research Organization (CRO) that designs and runs decentralized clinical trials. Through its Virtual Clinical Site and STRATUS platform, Curavit recruits, enrolls, and monitors diverse patient populations remotely - eliminating physical site infrastructure and travel while improving data quality. The company specializes in trials for digital therapeutics (DTx) and partners with sponsors and existing CROs to fix the execution layer of clinical research, accelerating timelines and lowering costs.
Hello Heart is a Menlo Park-based digital health company exclusively focused on cardiovascular health. Founded in 2013, it offers an AI-powered mobile app paired with a connected blood pressure monitor and smart pill box that helps members understand, track, and improve their heart health. Deployed through employers, health plans, and Medicare Advantage programs, Hello Heart has served users at 150+ Fortune 500 companies and government organizations. Independent peer-reviewed studies - including a JAMA study of 28,000+ participants - show that 84% of high-risk users reduced blood pressure over three years, with average medical cost savings exceeding $1,700 per enrolled member per year. The company has raised $148.5 million in total funding, most recently a $70 million Series D in May 2022.
Maayan Cohen is the Co-Founder and CEO of Hello Heart, a Menlo Park-based digital therapeutics company focused exclusively on cardiovascular health. A former Israeli tank platoon commander turned strategy consultant, she built Hello Heart from a 2013 startup into a platform covering 1.6+ million members across Fortune 500 employers, backed by $148.5M in funding from investors including Khosla Ventures, IVP, and Stripes. Named to CNBC Changemakers 2024 and Inc. Female Founders 500 in 2025, Cohen is recognized for her empathy-driven leadership style - including managing her company from Tel Aviv bomb shelters during the 2023 Israel-Hamas war while providing housing and support for both Israeli and Palestinian staff.
Bob Schafer, PhD, is the CEO of Lumos Labs, the company behind Lumosity, the world's largest brain training platform with over 100 million users. A Stanford-trained neuroscientist with postdoctoral work at MIT, Schafer founded Prophecy Sciences (YC W13) before joining Lumos Labs via acquihire in 2015. He rose from Head of Research to Chief Science Officer to President of Lumosity DTx before being named CEO in May 2023. Under his leadership, Lumos Labs achieved FDA 510(k) clearance in December 2025 for LumosityRx (marketed as Prismira), the first prescription digital therapeutic for attention improvement in adults with ADHD — validated by a 500-participant randomized controlled trial.